Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 15/20 | 0.62 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.59 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.59 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.53 |
| ▸ | CCR3 | P51677 | 1/20 | 0.53 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4201490 | 0.90 | CCR3 (0.66) | SIGMAR1MCHR1CCR3 | |
| SCHEMBL4206237 | 0.89 | SIGMAR1 (0.56) | SIGMAR1MCHR1SLC6A12TMEM97NPC1 | |
| SCHEMBL4205936 | 0.80 | CCR3 (0.64) | MCHR1CCR3 | |
| SCHEMBL5862050 | 0.77 | SIGMAR1 (1.00) | SIGMAR1CCR3 | |
| SCHEMBL8037825 | 0.77 | SIGMAR1 (1.00) | SIGMAR1CCR3 | |
| SCHEMBL4031095 | 0.77 | SIGMAR1 (0.74) | SIGMAR1NPC1RAB9ACCR3 | |
| SCHEMBL4199788 | 0.76 | SIGMAR1 (0.57) | SIGMAR1MCHR1SLC6A12CCR3 | |
| SCHEMBL4034703 | 0.75 | SIGMAR1 (0.62) | SIGMAR1MCHR1CCR3 | |
| SCHEMBL1425074 | 0.75 | SIGMAR1 (1.00) | SIGMAR1MCHR1SLC6A12TMEM97ATM | |
| SCHEMBL4215812 | 0.74 | NPC1 (0.57) | NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023733-A1 | Piperidine Derivatives, Their Process for Preparation, Their Use as Therapeutic Agents and Pharmaceutical Compositions Containing Them | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | disclosed |
| EP-1994002-A1 | PIPERIDINE DERIVATIVES, THEIR PROCESS FOR PREPARATION, THEIR USE AS THERAPEUTIC AGENTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AstraZeneca AB (SE) | 2008-11-26 | — | — | EP | disclosed |
| WO-2007102767-A1 | PIPERIDINE DERIVATIVES, THEIR PROCESS FOR PREPARATION, THEIR USE AS THERAPEUTIC AGENTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ASTRAZENECA AB (SE) | 2007-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023733-A1 | Piperidine Derivatives, Their Process for Preparation, Their Use as Therapeutic Agents and Pharmaceutical Compositions Containing Them | CCR3, CCR1, CCR5 | SIGMAR1 1718/4885MCHR1 1981/4885SLC6A12 4460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.